Core Insights - The presentation at the IIgANN2025 highlighted the significant clinical benefits of NEFECON (budesonide delayed-release capsules) for the long-term treatment of IgA nephropathy, supported by real-world data from top hospitals in China [1][2][3] Group 1: Treatment Efficacy - A retrospective study demonstrated that after 12 months of treatment with budesonide, patients showed a significant reduction in 24-hour urinary protein from 1016 mg to 114 mg, compared to 291 mg in the control group [2][3] - The estimated glomerular filtration rate (eGFR) slope for the budesonide group was significantly better at 5.4 ml/min/1.73m²/year versus -3.4 ml/min/1.73m²/year in the control group, indicating better kidney function preservation [2][3] - The study confirmed that budesonide treatment had a favorable safety profile, with no serious infections reported [2][3] Group 2: Clinical Guidelines and Recommendations - The 2025 version of the clinical practice guidelines for IgA nephropathy emphasizes the importance of controlling proteinuria in the short term and maintaining kidney function in the long term, highlighting the role of immunotherapy [3] - Budesonide is the only approved disease-modifying treatment for IgA nephropathy, recommended by both domestic and international guidelines for its mechanism of action in reducing pathogenic IgA production [3][4] Group 3: Market and Patient Demographics - There are over 5 million IgA nephropathy patients in China, with more than 100,000 new cases diagnosed annually, indicating a significant unmet clinical need [4] - NEFECON is the first and only disease-modifying treatment for IgA nephropathy approved in China, the US, and Europe, not limited by proteinuria levels, thus reshaping treatment pathways for patients [4]
IIgANN 2025：耐赋康 最新真实世界研究证实长期对因治疗持续展现良好有效性与安全性
Zhi Tong Cai Jing·2025-09-17 23:53